The estimated Net Worth of Alphonse Galdes is at least $949 Тысяча dollars as of 12 February 2021. Alphonse Galdes owns over 1,573 units of Biogen Inc stock worth over $948,664 and over the last 5 years he sold BIIB stock worth over $0. In addition, he makes $0 as Executive Vice President и Pharmaceutical Operations and Technology at Biogen Inc.
Sign up
Alphonse Galdes BIIB stock SEC Form 4 insiders trading
Alphonse has made over 3 trades of the Biogen Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,573 units of BIIB stock worth $313,169 on 12 February 2021.
The largest trade he's ever made was exercising 1,573 units of Biogen Inc stock on 12 February 2021 worth over $313,169. On average, Alphonse trades about 528 units every 61 days since 2020. As of 12 February 2021 he still owns at least 4,765 units of Biogen Inc stock.
You can see the complete history of Alphonse Galdes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alphonse Galdes biography
Dr. Alphonse Galdes is Executive Vice President, Pharmaceutical Operations and Technology of the Company. Galdes is Executive Vice President, Pharmaceutical Operations and Technology of Biogen and has served on the Executive Committee since September 2019. Since joining Biogen in 1995, Galdes has held several senior executive positions, including most recently as Senior Vice President, Asset Development and Portfolio Management from November 2015 to September 2019 and Senior Vice President, Technical Development from October 2010 to November 2015. Galdes received his B.S. in Chemistry and Biology and his M.S. in Biochemistry from the University of Malta and received his Ph.D. in Biochemistry from Oxford University, where he was a Rhodes Scholar. Galdes served as a Research Associate at the Department of Biological Chemistry at Harvard Medical School.
What's Alphonse Galdes's mailing address?
Alphonse's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Biogen Inc
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner и Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
What does Biogen Inc do?
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
What does Biogen Inc's logo look like?
Complete history of Alphonse Galdes stock trades at Biogen Inc
Biogen Inc executives and stock owners
Biogen Inc executives and other stock owners filed with the SEC include:
-
Michel Vounatsos,
Chief Executive Officer, Director -
Susan Alexander,
Executive Vice President, Chief Legal Officer and Secretary -
Alfred Sandrock,
Executive Vice President, Research and Development, Chief Medical Officer -
Chirfi Guindo,
Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation -
Michel Vounatsos,
CEO & Director -
Susan H. Alexander Esq.,
Exec. VP, Chief Legal Officer & Sec. -
Susan H. Alexander,
Exec. VP, Chief Legal Officer & Sec. -
Michael R. McDonnell,
Exec. VP & CFO -
Chirfi Guindo,
Exec. VP of Global Product Strategy & Commercialization -
Stelios Papadopoulos,
Independent Chairman of the Board -
Robert Pangia,
Independent Director -
Brian Posner,
Independent Director -
Alexander Denner,
Independent Director -
Nancy Leaming,
Independent Director -
Caroline Dorsa,
Independent Director -
Stephen Sherwin,
Independent Director -
Eric Rowinsky,
Independent Director -
Richard Mulligan,
Independent Director -
Jesus Mantas,
Independent Director -
William Hawkins,
Independent Director -
Robin Kramer,
Chief Accounting Officer, Vice President -
Daniel Karp,
Executive Vice President, Corporate Development -
Alphonse Galdes,
Executive Vice President, Pharmaceutical Operations and Technology -
Ginger Gregory,
Chief Human Resource Officer, Executive Vice President -
Michael McDonnell,
Chief Financial Officer, Executive Vice President -
Dr. Sanjay Jariwala,
Sr. VP of Worldwide Medical -
Nicole Murphy,
Head of Pharmaceutical Operations & Technology -
Dr. Anabella Villalobos Ph.D.,
Sr. VP of Biotherapeutic & Medicinal Sciences -
Dr. Alphonse Galdes,
Exec. VP of Pharmaceutical Operations & Technology -
Dr. Ginger Gregory,
Exec. VP & Chief HR Officer -
Natacha Gassenbach,
Chief Communication Officer & Head of Corp. Affairs -
Michael Hencke,
Director of Investor Relations -
Mark J. Hernon,
Sr. VP & Chief Information Officer -
Robin C. Kramer,
Sr. VP & Chief Accounting Officer -
George A Scangos,
Chief Executive Officer -
Adriana Karaboutis,
EVP, Tech. and Bus. Solutions -
Michael D Ehlers,
EVP, Research and Development -
Gregory F Covino,
VP, Chief Accounting Officer -
Lynn Schenk,
Director -
Paul Mc Kenzie,
EVP Pharmaceutical Oper & Tech -
Paul J Clancy,
CFO -
Kenneth Di Pietro,
EVP Human Resources -
Adam Koppel,
SVP, Chief Strategy Officer -
Susan Langer,
Director -
Jean Paul Kress,
EVP Pres Int'l & Global Hd GTO -
Priya Singhal,
Head of Development -
Jeffrey D Capello,
EVP & Chief Financial Officer -
Monish D Patolawala,
Director -
Phillip A Sharp,
Director -
Steven H Holtzman,
EVP Corp Devel and Strategy -
John Cox,
EVP Pharmaceutical Oper & Tech -
Spyridon Artavanis Tsakonas,
SVP, Chief Scientific Officer -
William Young,
Director -
Raymond Pawlicki,
SVP, Chief Information Officer -
Stuart A Kingsley,
EVP, Global Comm. Operations -
Douglas E Williams,
EVP Research & Development -
Craig Eric Schneier,
EVP, Human Resources -
Robert E. Gagnon,
Chief Acct Officer VP & Contr -
Francesco Granata,
EVP Global Commercial Operatio -
James C Mullen,
CEO and President -
Michael F Mac Lean,
SVP, Chief Accounting Officer -
Bruce Ross,
Director -
Robert A Hamm,
SVP, Immunology Business Unit -
Cecil B Pickett,
President, R & D -
Marijn E Dekkers,
Director -
Lawrence C Best,
Director -
Faheem Hasnain,
SVP, Oncology SBU -
Hans Peter Hasler,
SVP, International -
Mark C Wiggins,
EVP - Business Development -
Michael Lytton,
EVP Corporate & Business Devel -
Alan Glassberg,
Director -
John Michael Dunn,
EVP - New Ventures -
Michael Gilman,
EVP - Research -
Thomas J Bucknum,
EVP. General Counsel, Sec. -
Nabil Hanna,
EVP, Research -
William H Rastetter,
Executive Chairman -
William R Rohn,
Exec VP & COO -
Sylvie L Gregoire,
EVP, Bus. Dev & Program Mgmt. -
Burt A Adelman,
EVP, Development -
Alan Belzer,
Director -
Michael Kowolenko,
SVP, Pharm Ops & Technology -
Peter N Kellogg,
Executive Vice President, CFO -
Mary L Good,
Director -
Thomas F Keller,
Director -
Connie Matsui,
Sr V P, Planning& Resource Dev -
Christopher Viehbacher,
President and CEO -
Maria C Freire,
Director -
William D /Ca/ Jones,
Director -
Nicole Murphy,
Head of Pharm Ops and Tech -
Rachid Izzar,
Head of Global Product Strat. -
Adam Keeney,
Head of Corporate Development -
Jane Grogan,
Head of Research